Openbookopenbook
Equity
SOLTF
+0.0 · +0.00%
USD · PINK

Sosei Group Corporation(SOLTF) Stock Analysis | Healthcare

USD --+0.00%
Reward56Moderate
Risk53Moderate
75%Data
Thin -42% profit margin · Revenue growing 13% YoY
Profitless Growth
Market Cap:497.04M
ⓘ
Reward Rating
56
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
53
Moderate
Risk Assessment
8 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SOLTF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for SOLTF, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Sosei Group Corporation?

operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally.

SOLTF · Verdict

Solid reward · elevated risk

SOLTF stands out on growth and volatility, but watch the cash flow signal.

Based on 88% data coverage

SOLTF · Verdict

What’s working & what to watch

Strengths 2

  • Growth82/100

    Revenue +23.9% CAGR

  • Volatility75/100

    Above average

Watchouts 4

  • Cash flow16/100

    -11% free-cash-flow margin

  • Balance sheet26/100

    Current ratio 2.54

  • Profitability32/100

    -42% net margin · -19% ROE

  • Valuation33/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Sosei Group Corporation?

operates as a biopharmaceutical company, engages in drug discovery and development in Japan, the United States, Germany, Switzerland, Bermuda, the United Kingdom, and internationally. The company offers NxWave, a GPCR-targeted structure-based drug discovery platform; PIVLAZ for the cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aSAH; and QUVIVIQ for insomnia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 497.04M.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with growth and momentum as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

DNAMicro Cap / 498M market cap
Ginkgo Bioworks Holdings
Compare
CCCCMicro Cap / 494M market cap
C4 Therapeutics Inc
Compare
OABIMicro Cap / 491M market cap
OmniAb Inc.
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap497.04M
P/E RatioN/A
Dividend YieldN/A
Beta-0.065
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.